Growth in Life Sciences Services and Products
Double-digit growth in both Life Sciences Services and Life Sciences Product segments. Revenue from commercial cell and gene therapy grew 36% year-over-year to $8.3 million.
Expansion and New Product Launches
Launch of MVE Biological Solutions next-generation SC4/2V and SC4/3V vapor shippers. Opening of logistics portion of Cryoport Systems' new global supply chain center at Charles de Gaulle Airport in Paris.
Strategic Partnership with DHL
Progress in implementing the strategic partnership with DHL Group, enhancing positioning in APAC and EMEA regions.
Increased Clinical Trial Support
Supporting a record total of 745 global clinical trials, with 83 in Phase III, representing 70% of cell and gene therapy clinical trials.
Revenue Guidance Update
Full-year 2025 outlook updated to a range of $170 million to $174 million, reflecting 8% to 11% revenue growth over the prior year.